Cocrystal Pharma, Inc. (COCP) on Wednesday announced that it has appointed James Sapirstein chief executive officer, effective immediately, replacing co-chief executives Sam Lee and Jim Martin.
In pre-market activity on Nasdaq, shares of Cocrystal Pharma were up 5.60 percent, changing hands at $1.1088, after closing Tuesday's regular session 5.41 percent lower.
Sapirstein previously served as chief executive of Contravir Pharmaceuticals and Tobira Therapeutics. He has led 23 product launches and held senior roles at Gilead Sciences and Bristol Myers Squibb.
Following the management change, Lee will continue as president and become chief scientific officer, while Martin will remain chief financial officer.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.